Gregory Dietsch

USPTO Granted Patents = 11 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 29(Granted Patents)

Company Filing History:

7 out of 10

Ventirx Pharmaceuticals, Inc.

Sudo Biosciences Limited

patents

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12122785 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors (2024-10-22),

2. 12103937 - Substituted pyridines and pyridazines as TYK2 inhibitors (2024-10-01),

3. 12084458 - Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors (2024-09-10),

4. 11613548 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors (2023-03-28),

5. 9655904 - Substituted benzoazepines as toll-like receptor modulators (2017-05-23),

6. 9242964 - Substituted benzoazepines as toll-like receptor modulators (2016-01-26),

7. 9216192 - Toll-like receptor agonist formulations and their use (2015-12-22),

8. 9126940 - Substituted benzoazepines as toll-like receptor modulators (2015-09-08),

9. 8691809 - Substituted benzoazepines as toll-like receptor modulators (2014-04-08),

10. 8524702 - Substituted benzoazepines as toll-like receptor modulators (2013-09-03),

11. 8242106 - Toll-like receptor agonist formulations and their use (2012-08-14),

Title: Innovation Spotlight: Inventor Gregory Dietsch

Introduction:

Gregory Dietsch, a prolific inventor based in Snohomish, WA (US), has made significant contributions to the field of pharmaceuticals with a total of 8 patents to his name. His groundbreaking work in developing compounds for treating various diseases has garnered acclaim in the scientific community.

Latest Patents:

Dietsch's latest patents include "Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors" and "Substituted benzoazepines as toll-like receptor modulators." These patents focus on inhibiting TYK2 activity for treating certain conditions and modulating Toll-like receptors TLR7 and TLR8 for disease management.

Career Highlights:

Throughout his career, Dietsch has made significant strides in the biopharmaceutical industry. He has worked with renowned companies such as Ventirx Pharmaceuticals, Inc. and Array Biopharma Inc., where his innovative research has led to the development of potential life-saving medications.

Collaborations:

Dietsch has collaborated with esteemed professionals in the field, including Robert Hershberg and James Jeffry Howbert. Together, they have fueled advancements in immunotherapy and drug development, paving the way for new treatment modalities.

Conclusion:

Inventor Gregory Dietsch's relentless pursuit of innovation and his dedication to improving medical treatments have established him as a key figure in the pharmaceutical industry. His patents stand as a testament to his ingenuity and commitment to making a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.